BB BIOTECH AG
Q1 2019 13F Holdings
- Locationschaffhausen, V8
- Num holdings
35
- Value ($000)
$3,977,857
- Date Filed05/13/2019
- Form type13F-HR
- CIK0000924223
- All SEC filings
- NoteHoldings aggregated across “other managers” listed in original SEC filing, see here for detailed holdings broken out by other managers
Compare Q1 2019 toSelect Quarter
Issuer Name | Class | CUSIP | VALUE | % | Shares | Principal | Option Type |
|---|---|---|---|---|---|---|---|
Ionis Pharmaceuticals Inc. | COM | 462222100 | $627.04M | 16 % | 7,725,000 | ||
Incyte Corp. | COM | 45337C102 | $311.36M | 8 % | 3,620,000 | ||
Neurocrine Biosciences Inc. | COM | 64125C109 | $296.61M | 8 % | 3,366,786 | ||
Vertex Pharmaceuticals Inc | COM | 92532F100 | $239.14M | 6 % | 1,300,000 | ||
Sage Therapeutics, Inc. | COM | 78667J108 | $218.73M | 6 % | 1,375,229 | ||
Celgene Corp | COM | 151020104 | $207.55M | 5 % | 2,200,000 | ||
Agios Pharmaceuticals, Inc. | COM | 00847X104 | $200.85M | 5 % | 2,978,134 | ||
Alexion Pharmaceuticals, Inc. | COM | 015351109 | $177.68M | 5 % | 1,314,428 | ||
Alnylam Pharmaceuticals, Inc. | COM | 02043Q107 | $152.43M | 4 % | 1,631,089 | ||
Esperion Therapeutics, Inc. | COM | 29664W105 | $141.45M | 4 % | 3,522,964 |
Rows Per Page
10
- 5
- 10
- 20
- 30
- 50
- 100